Are there differences in hepatitis-B immunization status between diabetes and non-diabetes subjects in Korea?

Ji Young Park; Su Kyoung Kwon

doi:10.7180/kmj.2018.33.1.41

Articles

Page Path: HOME > Kosin Med J > Volume 33(1); 2018 > Article

Original Article Are there differences in hepatitis-B immunization status between diabetes and non-diabetes subjects in Korea?: Ji Young Park¹, Su Kyoung Kwon²; Kosin Medical Journal 2018;33(1):41-50.
DOI: https://doi.org/10.7180/kmj.2018.33.1.41
Published online: January 21, 2018

¹Department of Internal Medicine, Division of Infection, College of Medicine, Kosin University, Busan, Korea

²Department of Internal Medicine, Division of Endocrinology and Metabolism, College of Medicine, Kosin University, Busan, Korea

Corresponding Author: Su Kyoung Kwon, Department of Internal Medicine, College of Medicine, Kosin University, 262, Gamchen-ro, Seo-gu, Busan 49267, Korea Tel: +82-51-990-6712 Fax: +82-51-990-6712 E-mail: mir316@naver.com

• Received: October 21, 2016 • Accepted: December 26, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

1,439 Views
2 Download

prev next

Full Article

Download PDF

Abstract
References

Abstract

Objectives
The American Diabetes Association (ADA) recommends hepatitis-B virusVIruS vaccination for unvaccinated adults with diabetes. However, the Korean Diabetes Association (KDA) did not recommend hepatitis-B vaccination for unvaccinated adults with diabetes. This study was performed to assess the differences in hepatitis-B virus antigen and antibody status between Korean patients with diabetes and those without by using national survey data.
Methods
We analyzed hepatitis-B virus antigen and antibody status in 9,771 South Korean people from the general population based on the Korean National Health and Nutrition Examination Survey. Diabetes patients were defined as those with a measured fasting plasma glucose over 126 mg/dL or those who had been previously diagnosed with diabetes by other health care centers.
Results
Subjects with diabetes accounted for 812 (8.3%) among the 9771 study subjects. The prevalence ofhepatitis-B (HBsAg) seropositive subjects was not significantly different (3.9% vs. 4.6%, P = 0.09) between subjects with diabetes and those without. The prevalence of hepatitis-B antibody (HBsAb) positive subjects and unimmunized subjects was not significantly different (55.2% vs. 58.2%, P = 0.09, 40.9% vs. 37.2%, P = 0.09) between the two groups. The prevalence of unimmunized subjects decreased by age (< 20 years 33.3 % vs. 33.0%, 20~29 years 49.1% vs. 41.2%, 30~39 years 41.9% vs. 37.7%, 40~49 years 35.1% vs. 33.5%, 50~59 years 39.0% vs. 38.0%, 60~69 years 41.2% vs. 39.8%, > 70 years 48.5% vs. 42.8%) but was not significantly different between the 2 groups.
Conclusions
From this study, we conclude that there are not sufficient grounds to recommend routine hepatitis-B virus vaccination for unvaccinated Korean subjects with diabetes at this point in time in Korea. Further prospective studies will be needed.
Keywords: Diabetes; Hepatitis B; Immunization; Korean National Health and Nutrition

Fig. 1.

Distribution of hepatitis-B immunization status among diabetes and non-diabetes subjects.

Table 1.

Baseline characteristics of study subjects

Variables	Diabetes (n = 812)	Non diabetes (n = 8959)	P-value
Male : Female	415:397	4095:4864	0.021
Age, years	51.66 ± 15.67	37.91 ± 18.07	< 0.001
Weight, Kg	62.07 ± 10.81	58.8 ± 11.34	< 0.001
BMI, kg/m2	24.02 ± 3.41	22.47 ± 3.38	< 0.001
Waistcircumference(WC)	84.87 ± 9.34	77.75 ± 10.14	< 0.001
SBP, mmHg	134 ± 20.76	122.74 ± 18.75	< 0.001
DBP, mmHg	80.75 ± 12.44	75.99 ± 12.53	< 0.001
Pulserate, bpm	76.13 ± 10.88	74.02 ± 10.40	< 0.001
AST, U/L	51.66 ± 15.67	26.91 ± 18.52	< 0.001
ALT, U/L	33.84 ± 29.725	25.59 ± 21.30	< 0.001
Fastingbloodglucose, mg/dL	163.25 ± 62.04	93.65 ± 12.82	< 0.001
WBC, × 103/μL	6.15 ± 1.83	6.20 ± 18.28	0.947

Data are presented by mean ± standard deviation.

N, number; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm, beats per minuite; AST, aspartate aminotransferase; ALT, alanine aminotransferase; WBC, white blood cell.

Table 2.

Age and Obesity adjusted means of liver function

Variables	Diabetes (n = 812)	Non diabetes (n = 8959)	P-value
Aspartate aminotransferase, AST, SGOT*	30.71 ± 0.69	27.07 ± 0.21	< 0.001
Alanine aminotransferase, ALT, SGPT*	31.35 ± 0.75	25.83 ± 0.23	< 0.001
AST**	30.12 ± 0.69	27.13 ± 0.21	< 0.001
ALT**	30.17 ± 0.75	25.95 ± 0.23	< 0.001

Data are presented by mean ± standard error

^*Adujusted by age and body mass index.

^**Adjusted by age, body mass index and waist circumference.

Table 3.

Distribution of hepatitis-B immunization status according to different age groups by diabetes status

Age Groups	Non-diabetes			Diabetes			P-value
Age Groups	HBV carrier	Immunized	Non-immunized	HBV carrier	Immunized	Non-immunized	P-value
Total(%)	408 (4.6%)	5189(58.2%)	3313 (37.2%)	36 (3.9%)	477 (55.2%)	348 (40.9%)	0.169
<20	42 (2.4%)	1152 (64.6%)	588 (33.0%)	1 (3.7%)	17 (63%)	9 (33.3%)	0.898
20-30	81 (5.6%)	764 (53.1%)	593 (41.2%)	0 (0.0%)	28 (50.9%)	27 (49.1%)	0.140
30-40	115 (6.2%)	1033 (56.0%)	696 (37.7%)	8 (6.5%)	64 (51.6%)	52 (41.9%)	0.622
40-50	77 (5.1%)	918 (61.4%)	501 (33.5%)	5 (3.7%)	82 (61.2%)	47 (35.1%)	0.747
50-60	63 (6.0%)	588 (56.0%)	396 (38.0%)	6 (2.9%)	122 (58.1%)	82 (39.0%)	0.188
60-70	21 (2.5%)	486 (57.7%)	335 (39.8%)	10 (6.1%)	87 (52.7%)	68 (41.2%)	0.078
70-80	10 (2.5%)	218 (54.1%)	175 (43.4%)	1 (1.1%)	45 (51.1%)	42 (47.7%)	0.605
≥ 80	3 (3.2%)	54 (57.4%)	37 (39.4%)	1 (5.3%)	8 (42.1%)	10 (52.6%)	0.463

HBV, hepatitis B virus; Immunozed, HBsAg (-) and HBsAb (+); Non-immunized, HBsAg (-) and HBsAb (-)

References

1.Emerging Risk Factors Collaboration. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–41.Article PubMed PMC
2.American Diabetes Association. 3. Foundations of Care and Comprehensive Medical Evaluation. Diabetes Care 2016;39:S23–35.Article PubMed PDF
3.Treatment Guidelines for Diabetes (5th edition) [Internet] Korean Diabetes Association. Available from:.http://www.diabetes.or.kr/pro/pub-lishlguide.php?mode=list.
4.Bender TJ, Wise ME, Utah O, Moorman AC, Sharapov U, Drobeniuc J, et al. Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-Virginia, 2010. PLoS One 2012;7:e50012.Article PubMed PMC
5.Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:1709–11.PubMed
6.Jeong S, Yim HW, Bae SH, Lee WC. Changes of Hepatitis B Surface Antigen Seroprevalence in Korea, 1998-2005. Korean J Epidemiol 2008;30:119–27. Korean..Article
7.Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci TechnoI 2009;3:283–8.Article
8.Centers for Disease Control and Prevention(CDC). Transmission of hepatitis B VIruS among persons undergoing blood glucose monitoring in long-term--care facilities- Mississippi, North Carolina, and Los Angeles County, California, 2003-2004. MMWR Morb Mortal Wkly Rep 2005;54:220–3.Article PubMed
9.Reilly ML, Poissant T, Vonderwahl CW, Gerard K, Murphy TV. Incidence of acute hepatitis B among adults with and without diabetes, 2009-2010. 49th Annual Meeting of the Infectious Disease Society of America and the HIV Medicine Association; Boston, MA, October 2011.
10.Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AI. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262–5.Article PubMed
11.Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133:592–9.Article PubMed
12.Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 2005;28:2548–50.Article PubMed
13.Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992–1000.Article PubMed
14.El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–8.Article PubMed
15.Klonoff DC, Perz JF. Assisted monitoring of blood glucose: special safety needs for a new paradigm in testing glucose. J Diabetes Sci TechnoI 2010;4:1027–31.Article
16.Samandari T, Malakmadze N, Balter S, Perz IF, Khristova M, Swetnam L, et al. A large outbreak of hepatitis B virus infections associated with frequent injections at a physician's office. Infect Control Hosp Epidemiol 2005;26:745–50.Article PubMed
17.Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) partII: immunization of adults. MMWR Recomm Rep 2006;55(No.RR-16):1–13.

Figure & Data

References

Citations

Citations to this article as recorded by

PubReader
Cite

CITE

export Copy Format

Close

Download Citation

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.